- Lifecore Biomedical has signed a CDMO master services agreement with a new large global pharmaceutical customer covering development services and technology transfer for an injectable product.
- The agreement could position the partner among Lifecore’s top five commercial customers once commercial supply is transferred and regulatory requirements are met.
Lifecore Biomedical, Inc. has announced that it has entered into a CDMO master services agreement with a new large global pharmaceutical customer. Under the agreement, the company will provide development services and conduct technology transfer activities for an injectable pharmaceutical product, with the aim of moving commercial supply from overseas facilities to Lifecore’s sites.
According to the company, once commercial transfer activities are completed and all regulatory requirements are satisfied, Lifecore expects to become the commercial supplier of choice for the product. The agreement forms part of Lifecore’s contract manufacturing services for sterile injectable pharmaceuticals.
This is the second agreement Lifecore has signed in the past three months with a multinational pharmaceutical company. Based on current commercial revenues associated with the programme, the new customer has the potential to become one of Lifecore’s top five commercial customers.
“As we close 2025, we cannot be more excited to experience the momentum that has been generated by our talented business development team. Attracting and winning new business from two prominent pharmaceutical companies in quick succession speaks to our team’s ability to communicate our competitive differentiation in quality, technical expertise, and reliability for sterile injectables.”
Paul Josephs, chief executive officer of Lifecore
